MICROMET
Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.
MICROMET
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1993-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.cancervax.com
Status:
Closed
Contact:
+490898952770
Total Funding:
146.5 M USD
Current Advisors List
Stock Details
Investors List
Index Ventures
Index Ventures investment in Post-IPO Equity - Micromet
Merlin Nexus
Merlin Nexus investment in Post-IPO Equity - Micromet
NGN Capital
NGN Capital investment in Post-IPO Equity - Micromet
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Micromet
Abingworth
Abingworth investment in Post-IPO Equity - Micromet
Vector Fund Management
Vector Fund Management investment in Series C - Micromet
JPMorgan Partners
JPMorgan Partners investment in Series C - Micromet
Amerindo Investment Advisors
Amerindo Investment Advisors investment in Series C - Micromet
Forward Ventures
Forward Ventures investment in Series C - Micromet
SV Health Investors
SV Health Investors investment in Venture Round - Micromet
Official Site Inspections
http://www.cancervax.com Semrush global rank: 5.35 M Semrush visits lastest month: 1.56 K
- Host name: 172.67.69.37
- IP address: 172.67.69.37
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Micromet"
CancerVax - Wikipedia
CancerVax was an American pharmaceutical company founded in 1998 by Donald Morton. The company sought to develop a vaccine for cancer, and had candidates for melanoma reach phase III clinical trials. When those trials proved unsuccessful in 2005, the company soon underwent a reverse takeover with Micromet. See details»
CancerVAX 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for CancerVAX. Use the PitchBook Platform to explore the full profile.See details»
CancerVAX Biotech - Crunchbase Company Profile
CancerVAX Biotech is a biotechnology company that develops universal …See details»
CancerVAX Biotech - LinkedIn
At CancerVAX, we’re working to make cancer cells easier for the immune system to detect and destroy, without harming… Shared by CancerVAX Biotech Your …See details»
Investors - CancerVax
CancerVax, Inc. is a pre-clinical biotechnology company developing a novel Universal Cancer Treatment platform that will be customizable, as an …See details»
CancerVax - Overview, News & Similar companies | ZoomInfo.com
May 21, 2024 View CancerVax (www.cancervax.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
CancerVax - Crunchbase Company Profile & Funding
CancerVax is a biotechnology company focused on the research, development and commercialization of novel biological products.See details»
CancerVax Announces Successful Tests of its Smart …
Lehi, Utah – February 25, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the …See details»
Technology - CancerVax
The Solution We are developing a novel technology that will precisely detect cancer cells and force them to produce special proteins to “look” like common diseases for which a strong …See details»
Newsroom - CancerVax
Jan 13, 2025 CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it …See details»
CancerVAX
CancerVax is working with Cytiva to leverage its clinically proven LNPs to to create a complete CancerVax therapeutic nanoparticle. Axis Bio is a preclinical contract research organisation …See details»
Scientists Discuss the Recent CancerVax Breakthrough
Lehi, Utah, August 19, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today …See details»
About - CancerVax
CancerVax Team CancerVax is led by an experienced team of biotech experts, cancer researchers, and marketing executives who are working with development partners to create …See details»
Cancervax Corporation - SEC.gov
CancerVax also plans to identify and develop new product candidates based on its proprietary specific active immunotherapy, anti-angiogenesis and T-oligonucleotide, or telomere homolog …See details»
CancerVax Achieves Major Milestones and Files Foundational …
11 hours ago CancerVax was founded on the idea that disguising cancer cells to resemble foreign pathogens, such as the measles virus, could effectively “trick” the immune system into …See details»
CancerVax Passes First Test with Flying Colors - BioSpace
Dec 20, 2024 Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells Lehi, Utah, Dec. 20, 2024 …See details»
CancerVax Targets Liver Cancers to Further Showcase
Jun 9, 2025 CancerVax is a pre-clinical biotech company developing a novel Universal Cancer Treatment platform that will be customizable, as an injection, to treat many types of cancer.See details»
CancerVAX
These include, but are not limited to, risks and uncertainties associated with our history of losses and our need to raise additional financing, the acceptance of our products and technology in …See details»
CancerVAX
Working with a world class team of experienced cancer researchers and physicians, the CancerVax team asked the question, “What if we could create a universal cancer vaccine …See details»
Market - CancerVax
Market According to the World Health Organization, cancer is the second leading cause of death globally and was responsible for an estimated 10 million deaths in 2023. The American Cancer …See details»